C
옵티팜
153710KOSDAQ의료용품 및 기타 의약 관련제품 제조업48.5 / 100
Reference Date: 2026-04-13
Financial Score14.0 / 40
News Sentiment12.5 / 25
Momentum12.0 / 20
Disclosure10.0 / 15
AI Analysis: ROE is below the industry average, PBR raises overvaluation concerns. Slightly up 3.4% over the past month, with no recent news.
Company InformationBased on 2025 Annual Report
Business Overview
OptiPharm operates in multiple sectors including animal disease diagnosis, pharmaceutical development, bacteriophages, Medipig, and VLP vaccines, offering technology-driven services and products. The company differentiates itself through proprietary diagnostic systems, gene-editing technologies for transgenic animal development, and an efficient vaccine production system.
Number of Employees
79people
Average Salary
59.9M KRW
Score Calculation Basis
Detailed Financial Score
PER
—Industry Average 19.894.0Point
PBR
3.03Industry Average 1.621.0Point
1.9x industry avg (risky)
ROE
-9.48Industry Average -4.893.5Point
1.9x industry avg (good)
Debt Ratio
10.79Industry Average 8.882.0Point
Higher than industry avg (caution)
Trend 2023~20253.5 / 10 points
Revenue Growth Rate
2.5 / 3
Avg ▲13.4% (2-year basis)
Operating Profit Growth Rate
1.0 / 3
Avg ▲4.2% (2-year basis)
ROE Trend
0.0 / 4
Avg ROE -9.2% (declining, 3yr)
Detailed News Sentiment
0 totalPositive 0Neutral 0Negative 0
Detailed Momentum
52-week position3.0Point
52w lower range (28%)
Current 5,240Won52-week high 6,20052-week low 4,850
1-month return4.0Point
1m +3.35% (slight rise)
Volume trend5.0Point
Volume increasing
Detailed Disclosure
2 totalPositive 0Neutral 2Negative 0
- Neutral사외이사의선임ㆍ해임또는중도퇴임에관한신고2026-03-23
- Neutral정기주주총회결과2026-03-23